The Pharma world is seeing a big opportunity in GLP-1s – the new innovative fast emerging drugs for diabetes & obesity. Kiran ...

Nevertheless, European companies have found themselves in the sights of America’s president, who is irked by the fact that ...

Novo Nordisk was Europe's most valuable company, with a big lead on obesity drugs with its runaway hits Ozempic and Wegovy.

How Ozempic’s Maker Lost Its Grip on the Obesity Market It Created ...

Internationally, the scale is far smaller. There is not a single public company outside the US currently worth $1 trillion.

Just 14 stocks with market caps above $1 billion have doubled so far this year. They probably aren't the winners you would ...

Novo Nordisk NVO and Viking Therapeutics VKTX have emerged as notable players in the obesity space. A market leader in the ...

Eli Lilly's growth is impressive, but its current valuation is only justifiable with sustained high growth. Click here to ...

Denmark’s exports will grow clearly less than expected earlier, partly due to the setbacks Novo Nordisk A/S is facing in the ...

Novo Nordisk (NVO) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider ...

Novo Nordisk reduced its starter dose prices through telehealth platforms to encourage patients to wean themselves off compounded copycats.

LifeMD Collaborates with Novo Nordisk to Launch $299 Introductory Bundle for Self-Pay Patients Prescribed Wegovy® ...